The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

DKK 2016 | The balance between drug affordability and cancer care

Name: The balance between drug affordability and cancer care
Uploaded: 2016-02-25T00:00:00Z
Duration: 3 min 36 s
Description: Progress in the field of blood cancers has resulted in the rapid development of more effective, less toxic therapies. At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Rüdiger Hehlmann, MD, from Heidelberg University, Heidelberg, Germany, discusses some of the challenges posed by the rising cost of treatments.

Rüdiger Hehlmann • 25 Feb 2016

DKK 2016

Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Chronic Lymphocytic Leukemia Chronic Myeloid Leukemia

Progress in the field of blood cancers has resulted in the rapid development of more effective, less toxic therapies. At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Rüdiger Hehlmann, MD, from Heidelberg University, Heidelberg, Germany, discusses some of the challenges posed by the rising cost of treatments.